NFNanna Fridriksdottir

Nanna Fridriksdottir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nanna Fridriksdottir has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    International phase IV field study to validate the European Organisation for Research and Treatment of Cancer questionnaire for assessing the health-related quality of life of cancer survivors: The EORTC QLQ-SURV100

    by Louis Fox, Marieke van Leeuwen, Jennifer M. Jones, Amal Al-Omari, Haneen Abaza, Muna Al-Khaifi, Martin Eichler, Sue Hartup, Galina Velikova, Nanna Friðriksdóttir, et al.


  • Open Access

    Recruitment Strategies, Response Rates, and Non-Response Patterns in a Nationwide Registry-Based PRO Survey of Cancer Survivors and the General Population: The SURV-ICE Cohort

    by Kristjana Sigurðardóttir, Nanna Friðriksdóttir, Nanna Margrét Kristinsdóttir, Lára Kristjánsdóttir, Hjalti Gunnlaugur Skúlason, Álfheiður Haraldsdóttir, Sigríður Ása Alfonsdóttir, Anna Kristín B. Jóhannesdóttir, Helgi Birgisson, Helga Tryggvadóttir, et al.

    Background: Population-based studies using patient-reported outcomes provide important insights into health-related quality of life (HRQoL) and the long-term impact of cancer and its treatment. Declining response rates and potential non-response bias have presented methodological challenges, particularly in registry-based surveys including both cancer survivors and population controls. The SURV-ICE study was established to assess HRQoL and health literacy among cancer survivors in Iceland while evaluating recruitment processes and participation patterns in a nationwide mixed-mode survey. Methods: SURV-ICE is a nationwide, population-based cross-sectional survey conducted in Iceland in 2025. Adults diagnosed with invasive cancer between 2014 and 2024 were identified through the Icelandic Cancer Registry and invited alongside an age- and gender-matched control group sampled from national registers. Participants completed validated EORTC instruments. Recruitment used a mixed-mode strategy including postal invitations, web-based and paper questionnaires, electronic reminders via the national health portal, and targeted telephone follow-up. Results: Among 10,005 cancer survivors 5489 (54.9%) responded to the questionnaires and among 5663 controls 2297 (40.6%) responded to the questionnaires. In both groups participation peaked among individuals aged 60–79 years and was lowest among the youngest and oldest groups. Cancer survivors had higher odds of participation than controls (OR 1.84; 95% CI 1.72–1.97). Most responses followed the initial postal invitation and first electronic reminder. Data completeness was high (≥80% item completion in 95.7% of instruments). Conclusions: Nationwide registry-based recruitment for large-scale PRO research is feasible in Iceland and can achieve competitive response rates without incentives. SURV-ICE provides an infrastructure for future research on cancer survivorship, HRQoL, and health literacy.

  • Open Access

    Patient health engagement as a predictor of symptom outcomes in patients receiving chemotherapy

    by Nanna Fridriksdottir, Brynja Ingadottir, Sigridur Zoëga, Sigridur Gunnarsdottir

    Purpose Patient health engagement (PHE), reflecting psychological readiness to participate in care, may influence how patients cope with symptoms. This study explored the associations between PHE and symptom outcomes in cancer patients receiving outpatient chemotherapy. Methods A secondary analysis of baseline data was conducted among 79 patients with gastrointestinal or hematological cancers. PHE was assessed using the Patient Health Engagement Scale (PHE-s; range 1–4). Symptom intensity was measured using the Edmonton Symptom Assessment Scale-revised (ESASr), and daily life interference with the MD Anderson Symptom Inventory-Interference scale (MDASI). Multivariate regression models tested the predictive value of PHE, adjusting for psychosocial covariates, age, and cancer type. Results The mean PHE score was 3.1 (SD = 0.6; range 1.6–4.0), with one-third of patients scoring below 3, indicating low engagement. Higher PHE predicted lower overall symptom intensity (β = −0.42, p < 0.001), emotional symptoms (β = −0.56, p < 0.001), and interference in daily life (β = −0.46, p < 0.001). Although PHE was associated with physical symptom intensity (β = −0.29, p = 0.024), the overall model was not significant, and ROC analysis showed poor discrimination. ROC analyses identified domain-specific PHE cut-off scores (≤ 2.3–2.9) that distinguished between low and high symptom burden for total, emotional, and interference outcomes. Conclusion PHE, particularly psychological readiness, was associated with better overall, emotional, and functional symptom outcomes. Identifying patients with low engagement may enable more timely, tailored supportive care. Future research should validate these findings in larger and more diverse groups.

  • Open Access

    Supportive Digital Health Service During Cancer Chemotherapy: Single-Arm Before-and-After Feasibility Study

    by Nanna Fridriksdottir, Brynja Ingadottir, Kristin Skuladottir, Sigridur Zoëga, Sigridur Gunnarsdottir

    Background: Digital supportive cancer care is recommended to improve patient outcomes. A portal was designed and embedded within the electronic medical record and public health portal of Iceland, consisting of symptom and needs monitoring, educational material, and messaging. Objective: This study aims to assess (1) portal feasibility (adoption, engagement, usability, and acceptability), (2) potential predictors of usability and acceptability, and (3) the potential impact of the portal on patient-reported outcomes. Methods: This was a single-arm, before-and-after feasibility study at a university hospital among patients with cancer who were undergoing chemotherapy. Participation included filling out the Edmonton Symptom Assessment System–Revised (ESASr) weekly and the Distress Thermometer and Problem List (DT&PL) 3 times; reading educational material and messaging; and completing study questionnaires. Clinical and portal engagement data were collected from medical records. Data from patients were collected electronically at baseline and 7 to 10 days after the third chemotherapy round. Usability was assessed using the System Usability Scale (score 0-100), and acceptability was assessed using a 35-item survey (score 1-5). Patient-reported outcome measures included ESASr and DT&PL; a single-item scale for quality of life, family support, and quality of care; and multi-item scales for health literacy (Brief Health Literacy Screener), health engagement (Patient Health Engagement Scale), self-care self-efficacy (Self-Care Self-Efficacy scale), symptom interference (MD Anderson Symptom Inventory), knowledge expectations (Hospital Patients’ Knowledge Expectations), and received knowledge (Hospital Patients’ Received Knowledge). Health care professionals were interviewed regarding portal feasibility. Results: The portal adoption rate was 72% (103/143), and the portal use rate was 76.7% (79/103) over a mean 8.6 (SD 2.7) weeks. The study completion rate was 67% (69/103). The combined completion rate of the ESASr and DT&PL was 78.4% (685/874). Patients received a mean 41 (SD 13) information leaflets; 33% (26/79) initiated messaging, 73% (58/79) received messages, and 85% (67/79) received follow-up phone calls. The mean System Usability Scale score was 72.3 (SD 14.7), indicating good usability. Usability was predicted by age (β=−.45), ESASr engagement (β=.5), symptom interference (β=.4), and received knowledge (β=.41). The mean acceptability score, 3.97 (SD 0.5), was above average and predicted by age (β=−.31), ESASr engagement (β=.37), symptom interference (β=.60), self-care self-efficacy (β=.37), and received knowledge (β=.41). ESASr scores improved for total symptom distress (P=.003; Cohen d=0.36), physical symptoms (P=.01; Cohen d=0.31), and emotional symptoms (P=.01; Cohen d=0.31). Daily symptom interference increased (P=.03; Cohen d=0.28), quality of life improved (P=.03; Cohen d=0.27) and health engagement (P=.006; Cohen d=0.35) improved, while knowledge expectations decreased (P≤.001; Cohen d=2.57). Health care professionals were positive toward the portal but called for clearer role delineation and follow-up. Conclusions: This study supports the feasibility of a support portal and the results indicate the possibility of improving patient outcomes, but further developments are warranted.


  • Open Access

    Supportive Digital Health Service During Cancer Chemotherapy: Single-Arm Before-and-After Feasibility Study (Preprint)

    by Nanna Fridriksdottir, Brynja Ingadottir, Kristin Skuladottir, Sigridur Zoëga, Sigridur Gunnarsdottir

    BACKGROUND Digital supportive cancer care is recommended to improve patient outcomes. A portal was designed and embedded within the electronic medical record and public health portal of Iceland, consisting of symptom and needs monitoring, educational material, and messaging. OBJECTIVE This study aims to assess (1) portal feasibility (adoption, engagement, usability, and acceptability), (2) potential predictors of usability and acceptability, and (3) the potential impact of the portal on patient-reported outcomes. METHODS This was a single-arm, before-and-after feasibility study at a university hospital among patients with cancer who were undergoing chemotherapy. Participation included filling out the Edmonton Symptom Assessment System–Revised (ESASr) weekly and the Distress Thermometer and Problem List (DT&PL) 3 times; reading educational material and messaging; and completing study questionnaires. Clinical and portal engagement data were collected from medical records. Data from patients were collected electronically at baseline and 7 to 10 days after the third chemotherapy round. Usability was assessed using the System Usability Scale (score 0-100), and acceptability was assessed using a 35-item survey (score 1-5). Patient-reported outcome measures included ESASr and DT&PL; a single-item scale for quality of life, family support, and quality of care; and multi-item scales for health literacy (Brief Health Literacy Screener), health engagement (Patient Health Engagement Scale), self-care self-efficacy (Self-Care Self-Efficacy scale), symptom interference (MD Anderson Symptom Inventory), knowledge expectations (Hospital Patients’ Knowledge Expectations), and received knowledge (Hospital Patients’ Received Knowledge). Health care professionals were interviewed regarding portal feasibility. RESULTS The portal adoption rate was 72% (103/143), and the portal use rate was 76.7% (79/103) over a mean 8.6 (SD 2.7) weeks. The study completion rate was 67% (69/103). The combined completion rate of the ESASr and DT&PL was 78.4% (685/874). Patients received a mean 41 (SD 13) information leaflets; 33% (26/79) initiated messaging, 73% (58/79) received messages, and 85% (67/79) received follow-up phone calls. The mean System Usability Scale score was 72.3 (SD 14.7), indicating good usability. Usability was predicted by age (β=−.45), ESASr engagement (β=.5), symptom interference (β=.4), and received knowledge (β=.41). The mean acceptability score, 3.97 (SD 0.5), was above average and predicted by age (β=−.31), ESASr engagement (β=.37), symptom interference (β=.60), self-care self-efficacy (β=.37), and received knowledge (β=.41). ESASr scores improved for total symptom distress (P=.003; Cohen d=0.36), physical symptoms (P=.01; Cohen d=0.31), and emotional symptoms (P=.01; Cohen d=0.31). Daily symptom interference increased (P=.03; Cohen d=0.28), quality of life improved (P=.03; Cohen d=0.27) and health engagement (P=.006; Cohen d=0.35) improved, while knowledge expectations decreased (P≤.001; Cohen d=2.57). Health care professionals were positive toward the portal but called for clearer role delineation and follow-up. CONCLUSIONS This study supports the feasibility of a support portal and the results indicate the possibility of improving patient outcomes, but further developments are warranted.

  • The effectiveness of the Pain Resource Nurse Program to improve pain management in the hospital setting: A cluster randomized controlled trial

    by Sigridur Gunnarsdottir, Sigridur Zoëga, Ronald C. Serlin, Herdis Sveinsdottir, Elin Johanna Gudrun Hafsteinsdottir, Nanna Fridriksdottir, Elfa Tholl Gretarsdottir, Sandra Evelyn Ward


  • Effects of web-based interventions on cancer patients’ symptoms: review of randomized trials

    by N. Fridriksdottir, S. Gunnarsdottir, S. Zoëga, B. Ingadottir, E. J. G. Hafsteinsdottir

    Symptom management is of high priority in cancer care. Information and communication technology allows interventions to be provided through the internet to enhance the delivery of care. This study aimed to review the effects of web-based interventions on cancer patients’ symptoms.


  • Changes in attitudes, practices and barriers among oncology health care professionals regarding sexual health care: Outcomes from a 2-year educational intervention at a University Hospital

    by Jona Ingibjorg Jonsdottir, Sigridur Zoëga, Thorunn Saevarsdottir, Asgerdur Sverrisdottir, Thora Thorsdottir, Gudmundur Vikar Einarsson, Sigridur Gunnarsdottir, Nanna Fridriksdottir


  • Pain and other symptoms and their relationship to quality of life in cancer patients on opioids

    by Sigridur Zoëga, Nanna Fridriksdottir, Valgerdur Sigurdardottir, Sigridur Gunnarsdottir

    Purpose The purpose of this study was to assess pain, other symptoms and QOL, and the relationship between these variables, among cancer patients on strong opioids. Methods The study was cross-sectional, descriptive, and correlational. A convenience sample of 150 cancer patients, ≥18 years, all on strong opioids for ≥3 days was recruited. Results The mean (SD) age was 64.7 (12.7) years, and 59 % were women. Mean (SD) time from cancer diagnosis was 36.3 (55.1) months. The median number of symptoms was 9, range 1–16 and the mean (SD) severity was 1.9 (0.5) on a 1–4 scale. Pain was one of the most prevalent (90 %) and severe symptoms with a mean (SD) of 2.56 (0.9). Number of symptoms explained 25.8 % of the variance in QOL, adjusted for age and sex. Another model, also adjusted for age and sex, showed that pain, fatigue, insomnia and depression, explained 33.6 % of the variance in QOL. Conclusions The symptomatology in this study was similar to studies on patients with advanced cancer. QOL was associated with the number of symptoms patients experience and individual symptoms, notably fatigue and pain. Despite the use of strong opioids, pain was both common and severe, suggesting under-treatment. Pain and other symptoms need to be assessed and managed in order to improve patients’ QOL. Special attention needs to be paid to multisymptom management in patients on opioids.